drugset / Trial / NCT03580902

CBT4CBT for Office Based Buprenorphine

NCT03580902

Phase 1/2 Completed 51 enrolled CBT4CBT, LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

In this Phase II SBIR/STTR project, our Specific Aim will be to determine if the use of CBT4CBT-Buprenorphine leads to clinically significant improved outcomes and increased retention for buprenorphine maintenance patients in a larger and diverse population of individuals seeking buprenorphine treatment in primary care (N=100).

Timeline

Start
2019-01-22
Primary completion
2021-11-23
Completion
2022-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified
Background Naloxone Small molecule

Indications